Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma.

Pan S, Mirchia K, Payne E, Liu SJ, Al-Adli N, Peeran Z, Shukla P, Young JS, Gupta R, Wu J, Pak J, Ozawa T, Na B, Reddy AT, Braunstein SE, Phillips JJ, Chang S, Solomon DA, Perry A, Raleigh DR, Berger MS, Abate AR, Vasudevan HN